AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

We recently announced that Roswell Park Comprehensive Cancer Center was awarded $14.5 million to enable five new phase II or phase IIA clinical trials to assess the efficacy of a multipronged approach for metastatic colorectal cancer, checkpoint-resistant advanced melanoma, and advanced ovarian cancer. The clinical trials will employ a chemokine-modulating regimen targeting three separate pathways of immune response — the toll-like receptor-3, type-1 interferon and prostaglandin networks — as well as specialized dendritic-cell therapeutic vaccines. We are providing Ampligen (rintatolimod) as a chemokine-modulating agent for these studies.

Read Roswell Park’s full announcement here:

Hemispherx News 04

Need More Info?

Let’s Talk